Systematic Review: Genetic, Neuroimaging, and Fluids Biomarkers for Frontotemporal Dementia Across Latin America Countries
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Frontotemporal dementia (FTD) includes a group of clinically, genetically, and pathologically heterogeneous neurodegenerative disorders, affecting the fronto-insular-temporal regions of the brain. Clinically, FTD is characterized by progressive deficits in behavior, executive function, and language and its diagnosis relies mainly on the clinical expertise of the physician/consensus group and the use of neuropsychological tests and/or structural/functional neuroimaging, depending on local availability. The modest correlation between clinical findings and FTD neuropathology makes the diagnosis difficult using clinical criteria and often leads to underdiagnosis or misdiagnosis, primarily due to lack of recognition or awareness of FTD as a disease and symptom overlap with psychiatric disorders. Despite advances in understanding the underlying neuropathology of FTD, accurate and sensitive diagnosis for this disease is still lacking. One of the major challenges is to improve diagnosis in FTD patients as early as possible. In this context, biomarkers have emerged as useful methods to provide and/or complement clinical diagnosis for this complex syndrome, although more evidence is needed to incorporate most of them into clinical practice. However, most biomarker studies have been performed using North American or European populations, with little representation of the Latin American and the Caribbean (LAC) region. In the LAC region, there are additional challenges, particularly the lack of awareness and knowledge about FTD, even in specialists. Also, LAC genetic heritage and cultures are complex, and both likely influence clinical presentations and may modify baseline biomarker levels. Even more, due to diagnostic delay, the clinical presentation might be further complicated by both neurological and psychiatric comorbidity, such as vascular brain damage, substance abuse, mood disorders, among others. This systematic review provides a brief update and an overview of the current knowledge on genetic, neuroimaging, and fluid biomarkers for FTD in LAC countries. Our review highlights the need for extensive research on biomarkers in FTD in LAC to contribute to a more comprehensive understanding of the disease and its associated biomarkers. Dementia research is certainly reduced in the LAC region, highlighting an urgent need for harmonized, innovative, and cross-regional studies with a global perspective across multiple areas of dementia knowledge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resources for mental health: scarcity, inequity, and inefficiency
Saxena, S., Thornicroft, G., Knapp, M., & Whiteford, H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61239-2 · Cited by 1,789 · cited 1×
“Barriers to diagnosis in the region include inadequate training (7, 8), especially among primary care physicians (2, 9), together with insufficient access to both healthcare and specialized services such as neuropsychological assessment (2, 6).”
BackgroundNeuroinflammation: The Devil Is in the Details
DiSabato, D. J., Quan, N., & Godbout, J. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13607 · Cited by 1,640 · cited 1×
“Biomarkers include some of the pro- and antiinflammatory cytokines, chemokines, and secondary messengers that coordinate the immune response through regulation of innate and adaptive responses in the periphery (188, 189).”
BackgroundPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 1×
“92 with a specificity of 81% and sensitivity of 93% to differentiate between these variants of FTD and AD (173).”
BackgroundInnate immune activation in neurodegenerative disease
Heneka, M. T., Kummer, M. P., & Latz, E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3705 · Cited by 1,437 · cited 1×
“It has been suggested that immune activation may be an early cause of neurodegeneration (180) or that the addition or accumulation of tau or TDP-43 induces an increased cytotoxic response leading to chronic neuroinflammation (181–183).”
BackgroundLong pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43
Polymenidou, M., Lagier-Tourenne, C., Hutt, K. R., Huelga, S. C., Moran, J., Liang, T. Y., Ling, S.-C., Sun, E., Wancewicz, E., Mazur, C., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2779 · Cited by 1,335
Kalaria, R. N., Maestre, G. E., Arizaga, R., Friedland, R. P., Galasko, D., Hall, K., Luchsinger, J. A., Ogunniyi, A., Perry, E. K., Potocnik, F., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70169-8 · Cited by 1,233
Majounie, E., Renton, A. E., Mok, K., Dopper, E. G., Waite, A., Rollinson, S., Chiò, A., Restagno, G., Nicolaou, N., Simon-Sanchez, J., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70043-1 · Cited by 1,210 · cited 1×
“In Europe and North America, the C9orf72 expansion accounted for nearly 40% of familial and 8% of sporadic ALS, as well as 25% of familial and 6% of sporadic FTD cases (64).”
BackgroundBang, J., Spina, S., & Miller, B. L. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00461-4 · Cited by 1,144
Hol, E. M., & Pekny, M. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.02.004 · Cited by 917
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 1×
“One study also found that CSF sTREM2 levels decreased in a larger cohort of patients with FTD, including carriers with C9orf72 and GRN mutations (204).”
BackgroundInflammatory Response in the CNS: Friend or Foe?
Sochocka, M., Diniz, B. S., & Leszek, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0297-1 · Cited by 573
The heritability and genetics of frontotemporal lobar degeneration
Rohrer, J. D., Guerreiro, R., Vandrovcova, J., Uphill, J., Reiman, D., Beck, J., Isaacs, A. M., Authier, A., Ferrari, R., Fox, N. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bf997a · Cited by 536 · cited 3×
“Genetics Biomarkers for FTD in LAC A strong genetic component has been observed in FTD, where 20–30% of cases have an autosomal dominant inheritance (26, 27, 58).”
BackgroundAn update on genetic frontotemporal dementia
Greaves, C. V., & Rohrer, J. D. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09363-4 · Cited by 500
Gisslén, M., Price, R. W., Andreasson, U., Norgren, N., Nilsson, S., Hagberg, L., Fuchs, D., Spudich, S., Blennow, K., & Zetterberg, H. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2015.11.036 · Cited by 481
TREM2 in Neurodegenerative Diseases
Jay, T. R., von Saucken, V. E., & Landreth, G. E. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0197-5 · Cited by 427
MAPT mutations, tauopathy, and mechanisms of neurodegeneration
Strang, K. H., Golde, T. E., & Giasson, B. I. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0197-x · Cited by 424
Olney, N. T., Spina, S., & Miller, B. L. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.008 · Cited by 419
Guerreiro, R. J., Lohmann, E., Brás, J. M., Gibbs, J. R., Rohrer, J. D., Gurunlian, N., Dursun, B., Bilgic, B., Hanagasi, H., Gurvit, H., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.579 · Cited by 374 · cited 1×
“These mutations of TREM2 have also been associated with FTD-like presentations without bone involvement (95, 96).”
BackgroundCerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Piccio, L., Deming, Y., Del-Águila, J. L., Ghezzi, L., Holtzman, D. M., Fagan, A. M., Fenoglio, C., Galimberti, D., Borroni, B., & Cruchaga, C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1533-5 · Cited by 337 · cited 1×
“In carriers of TREM2 mutations, sTREM2 CSF levels are decreased, suggesting a loss of function as a pathological mechanism (203).”
BackgroundEpidemiology of early-onset dementia: a review of the literature
Vieira, R. T., Caixeta, L., Machado, S., Silva, A. C., Nardi, A. E., Arias-Carrión, O., & Carta, M. G. (2013) · Clinical Practice & Epidemiology in Mental Health · doi:10.2174/1745017901309010088 · Cited by 325 · cited 1×
“dementia (14, 15), with a prevalence ranging from 3 to 26% described in North America and European populations (16, 17).”
BackgroundIntrathecal Chemokine Synthesis in Mild Cognitive Impairment and Alzheimer Disease
Galimberti, D., Schoonenboom, N., Scheltens, P., Fenoglio, C., Bouwman, F., Venturelli, E., Guidi, I., Blankenstein, M. A., Bresolin, N., & Scarpini, E. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.538 · Cited by 289 · cited 2×
“Reports of elevated CSF levels from TGF-β and IL-11 (192, 197) have not yet been reproduced or denied, while two studies have identified elevated CSF levels from CCL2 in sporadic FTD (194, 196).”
BackgroundNeurofilament light chain: a biomarker for genetic frontotemporal dementia
Meeter, L. H., Dopper, E. G., Jiskoot, L. C., Sanchez‐Valle, R., Graff, C., Benussi, L., Ghidoni, R., Pijnenburg, Y. A., Borroni, B., Galimberti, D., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.325 · Cited by 263 · cited 1×
“NfL concentration only increases during the symptomatic phase, while pre-symptomatic levels are usually similar to controls (142).”
BackgroundCSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival
Skillbäck, T., Farahmand, B., Bartlett, J. W., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001015 · Cited by 263 · cited 1×
“NfL levels in CSF in patients with bvFTD are higher than in MCI, AD, and controls (48), which has been described in other studies (145, 147, 148).”
ResultScherling, C. S., Hall, T., Berisha, F., Klepac, K., Karydas, A., Coppola, G., Kramer, J. H., Rabinovici, G., Ahlijanian, M., Miller, B. L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24052 · Cited by 249 · cited 1×
“NfL levels in CSF in patients with bvFTD are higher than in MCI, AD, and controls (48), which has been described in other studies (145, 147, 148).”
ResultEstimating the Number of Persons with Frontotemporal Lobar Degeneration in the US Population
Knopman, D. S., & Roberts, R. O. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9538-y · Cited by 236 · cited 3×
“Regarding clinical diagnosis, as mentioned, FTD is often underdiagnosed (15, 20, 21).”
BackgroundImaging and fluid biomarkers in frontotemporal dementia
Meeter, L. H., Kaat, L. D., Rohrer, J. D., & van Swieten, J. C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.75 · Cited by 210 · cited 1×
“Other biomarkers could also be used to tailor pharmacological treatment or determinate prognosis (30).”
BackgroundFleisher, A. S., Chen, K., Liu, X., Ayutyanont, N., Roontiva, A., Thiyyagura, P., Protas, H., Joshi, A. D., Sabbagh, M., Sadowsky, C. H., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.017 · Cited by 202
García-Cordero, I., Sedeño, L., de la Fuente, L., Slachevsky, A., Forno, G., Klein, F., Lillo, P., Ferrari, J., Rodriguez, C., Bustin, J., et al. (2016) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0006 · Cited by 199
Self-citationSteinacker, P., Hendrich, C., Sperfeld, A. D., Jesse, S., von Arnim, C. A. F., Lehnert, S., Pabst, A., Uttner, I., Tumani, H., Lee, V. M.-Y., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1481 · Cited by 199
In vivo detection of microglial activation in frontotemporal dementia
Cagnin, A., Rossor, M., Sampson, E. L., MacKinnon, T., & Banati, R. B. (2004) · Annals of Neurology · doi:10.1002/ana.20332 · Cited by 187 · cited 1×
“Patients with FTD show overexpression of tumor necrosis factor (TNF) and transforming growth factor (TGF-b1) in CSF, as well as microglia activation in atrophic areas of the brain (190, 191).”
BackgroundPlasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia
Heller, C., Foiani, M. S., Moore, K., Convery, R., Bocchetta, M., Neason, M., Cash, D. M., Thomas, D., Greaves, C. V., Woollacott, I. O., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321954 · Cited by 182 · cited 2×
“In symptomatic stages, higher GFAP concentrations were associated with faster rates of atrophy, suggesting that GFAP could be associated with disease intensity, progression, and survival (176).”
BackgroundCytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
Sjögren, M., Rosengren, L., Minthon, L., Davidsson, P., Blennow, K., & Wallin, A. (2000) · Neurology · doi:10.1212/wnl.54.10.1960 · Cited by 181
van der Ende, E. L., Meeter, L. H., Poos, J. M., Panman, J. L., Jiskoot, L. C., Dopper, E. G. P., Papma, J. M., de Jong, F. J., Verberk, I. M. W., Teunissen, C., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30354-0 · Cited by 181 · cited 5×
“These results were validated in subjects symptomatic and presymptomatic mutation carriers of C9orf72 and MAPT, in addition to GRN carriers (143).”
BackgroundResultInfluentialTDP-43 frontotemporal lobar degeneration and autoimmune disease
Miller, Z. A., Rankin, K. P., Graff-Radford, N. R., Takada, L. T., Sturm, V. E., Cleveland, C. M., Criswell, L. A., Jaeger, P. A., Stan, T., Heggeli, K. A., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304644 · Cited by 170
Self-citationGuerreiro, R., Bilgic, B., Guven, G., Brás, J., Rohrer, J., Lohmann, E., Hanagasi, H., Gurvit, H., & Emre, M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.005 · Cited by 158 · cited 1×
“Homozygous or compound heterozygous mutations of TREM2 have been associted to Nasu-Hakola disease which is characterized by bone involvement with an early-onset FTD phenotype (93, 94).”
BackgroundIshiki, A., Kamada, M., Kawamura, Y., Terao, C., Shimoda, F., Tomita, N., Arai, H., & Furukawa, K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13399 · Cited by 156 · cited 1×
“Increased levels of GFAP have been reported in AD and ALS patients in both CSF and serum (57, 177).”
BackgroundGiraldo, M., Lopera, F., Siniard, A. L., Corneveaux, J. J., Schrauwen, I., Carvajal, J., Muñoz, C., Ramirez-Restrepo, M., Gaiteri, C., Myers, A. J., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.02.016 · Cited by 147
Karikari, T. K., Emeršič, A., Vrillon, A., Lantero‐Rodriguez, J., Ashton, N. J., Kramberger, M. G., Dumurgier, J., Hourregue, C., Čučnik, S., Brinkmalm, G., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12236 · Cited by 143 · cited 2×
“In a recent study, plasma p-tau181 distinguished AD of DFT with an AUC of 100% (172), suggesting that this protein could be used as a potential diagnosis tool, however no studies of this protein has been developed in the LAC region.”
BackgroundOeckl, P., Weydt, P., Steinacker, P., Anderl-Straub, S., Nordin, F., Volk, A. E., Diehl-Schmid, J., Andersen, P. M., Kornhuber, J., Danek, A., et al. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318868 · Cited by 139
The Role of Neuroinflammation in Dementias
Pasqualetti, G., Brooks, D. J., & Edison, P. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0531-7 · Cited by 133
Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia
Landqvist Waldö, M., Frizell Santillo, A., Passant, U., Zetterberg, H., Rosengren, L., Nilsson, C., & Englund, E. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-54 · Cited by 127 · cited 1×
“NfL levels in CSF in patients with bvFTD are higher than in MCI, AD, and controls (48), which has been described in other studies (145, 147, 148).”
ResultSjogren, M. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.019422 · Cited by 125 · cited 5×
“Galimberti D, Venturelli E, Fenoglio C, Guidi I, Villa C, Bergamaschini L, et al. Intrathecal levels of IL-6, IL-11 and LIF in alzheimer’s disease and frontotemporal lobar degeneration.”
BackgroundInfluentialCSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration
Alcolea, D., Vilaplana, E., Suárez-Calvet, M., Illán-Gala, I., Blesa, R., Clarimón, J., Lladó, A., Sánchez-Valle, R., Molinuevo, J. L., García-Ribas, G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004088 · Cited by 123
CSF neurofilament proteins in the differential diagnosis of dementia
de Jong, D., Jansen, R. W. M. M., Pijnenburg, Y. A. L., van Geel, W. J. A., Borm, G. F., Kremer, H. P. H., & Verbeek, M. M. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.107326 · Cited by 120
Serum neurofilament light chain in behavioral variant frontotemporal dementia
Steinacker, P., Anderl-Straub, S., Diehl-Schmid, J., Semler, E., Uttner, I., von Arnim, C. A. F., Barthel, H., Danek, A., Fassbender, K., Fliessbach, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006318 · Cited by 116
Comparing moral judgments of patients with frontotemporal dementia and frontal stroke
Baez, S., Couto, B., Torralva, T., Sposato, L. A., Huepe, D., Montañes, P., Reyes, P., Matallana, D., Vigliecca, N. S., Slachevsky, A., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.347 · Cited by 93 · cited 1×
“Reports from LAC in this domain have shown neurocognitive deficits in FTD related tofacial emotion recognition (106–109), empathy (34, 110–112), theory of mind (106, 107, 112), moral judgment (35, 113), moral emotions (114), and interoception (115).”
BackgroundSelf-citationPijnenburg, Y. A. L., Verwey, N. A., van der Flier, W. M., Scheltens, P., & Teunissen, C. E. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.11.001 · Cited by 91 · cited 3×
“Elevated levels of TDP-43 have been observed in CSF in patients with Frontiers in Neurology | www.frontiersin.org 8 June 2021 | Volume 12 | Article 663407 ALS and FTD, with higher concentrations in ALS than in FTD, suggesting that TDP-43 is a biomarker in this disease (162).”
BackgroundAguirre-Acevedo, D. C., Lopera, F., Henao, E., Tirado, V., Muñoz, C., Giraldo, M., Bangdiwala, S. I., Reiman, E. M., Tariot, P. N., Langbaum, J. B., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4851 · Cited by 90
Beyond the face: how context modulates emotion processing in frontotemporal dementia subtypes
Kumfor, F., Ibañez, A., Hutchings, R., Hazelton, J. L., Hodges, J. R., & Piguet, O. (2018) · Brain · doi:10.1093/brain/awy002 · Cited by 89
Progranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers
Meeter, L. H. H., Patzke, H., Loewen, G., Dopper, E. G. P., Pijnenburg, Y. A. L., van Minkelen, R., & van Swieten, J. C. (2016) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000447738 · Cited by 87
More than words: social cognition across variants of primary progressive aphasia
Fittipaldi, S., Ibanez, A., Baez, S., Manes, F., Sedeno, L., & Garcia, A. M. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.02.020 · Cited by 82
Cerami, C., Iaccarino, L., & Perani, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050993 · Cited by 75
Dottori, M., Sedeño, L., Martorell Caro, M., Alifano, F., Hesse, E., Mikulan, E., García, A. M., Ruiz-Tagle, A., Lillo, P., Slachevsky, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04204-8 · Cited by 73
Self-citationFatigue in multiple sclerosis is associated with multimodal interoceptive abnormalities
Gonzalez Campo, C., Salamone, P. C., Rodríguez-Arriagada, N., Richter, F., Herrera, E., Bruno, D., Pagani Cassara, F., Sinay, V., García, A. M., Ibáñez, A., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458519888881 · Cited by 70
Self-citationRentzos, M., Zoga, M., Paraskevas, G. P., Kapaki, E., Rombos, A., Nikolaou, C., Tsoutsou, A., & Vassilopoulos, D. (2006) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988706286226 · Cited by 65
Moguilner, S., García, A. M., Perl, Y. S., Tagliazucchi, E., Piguet, O., Kumfor, F., Reyes, P., Matallana, D., Sedeño, L., & Ibáñez, A. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2020.117522 · Cited by 63 · cited 1×
“Another similar non-linear connectivity method has been proven robust to classify FTD patients based on the dynamical fluctuation assessed with machine learning (130).”
Self-citationMapping neuroinflammation in frontotemporal dementia with molecular PET imaging
Zhang, J. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0236-5 · Cited by 62
Bachli, M. B., Sedeño, L., Ochab, J. K., Piguet, O., Kumfor, F., Reyes, P., Torralva, T., Roca, M., Cardona, J. F., Campo, C. G., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2019.116456 · Cited by 57
Self-citationSedeño, L., Piguet, O., Abrevaya, S., Desmaras, H., García‐Cordero, I., Baez, S., Alethia de la Fuente, L., Reyes, P., Tu, S., Moguilner, S., et al. (2017) · Human Brain Mapping · doi:10.1002/hbm.23627 · Cited by 55 · cited 2×
“In LAC, this technique had no gold standard reported until a group from Argentina conducted a multicenter analysis of functional imaging in bvFTD (53).”
BackgroundMethodSelf-citationFTD spectrum: Neuroimaging across the FTD spectrum
Whitwell, J. L. (2019) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2019.05.009 · Cited by 53 · cited 9×
“Fluid Biomarkers MRI, cortical thickness, NfL in CSF Unspecified Riudavets et al. (49) 2013 10.1111/bpa.12051 Argentina Genetics PS-1 Unspecified Santamaria-Garcia et al. (50) 2016 10.3233/JAD-160501 Colombia, Argentina, Chile Neuroimaging VBM Neuropsychiatric symptoms Santos et al. (51) 2014 10.1016/j.pnpbp.2013.06.0…”
BackgroundInfluentialReview: Fluid biomarkers for frontotemporal dementias
Zetterberg, H., van Swieten, J. C., Boxer, A. L., & Rohrer, J. D. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12530 · Cited by 48 · cited 1×
“As mentioned, the diagnosis of FTD is particularly challenging because the relationship between clinical symptoms, pathology, and genetic causes are complex (31, 55, 56).”
BackgroundEyigoz, E., Courson, M., Sedeño, L., Rogg, K., Orozco-Arroyave, J. R., Nöth, E., Skodda, S., Trujillo, N., Rodríguez, M., Rusz, J., et al. (2020) · Cortex · doi:10.1016/j.cortex.2020.08.020 · Cited by 44
Self-citationGossye, H., Van Broeckhoven, C., & Engelborghs, S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00757 · Cited by 34
Abrevaya, S., Fittipaldi, S., García, A. M., Dottori, M., Santamaria-Garcia, H., Birba, A., Yoris, A., Hildebrandt, M. K., Salamone, P., De la Fuente, A., et al. (2020) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000868 · Cited by 34
Self-citationBertoux, M., Flanagan, E. C., Hobbs, M., Ruiz-Tagle, A., Delgado, C., Miranda, M., Ibáñez, A., Slachevsky, A., & Hornberger, M. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170771 · Cited by 28 · cited 1×
“A multinational team of researchers, including participants from Chile and France, aimed to identify and discriminate the structural anatomical markers of episodic memory impairment in bvFTD, comparing those patients with AD patients and healthy controls, finding that impairment of medial/lateral temporal atrophy is a…”
BackgroundSelf-citationSu, W., Shi, Z., Liu, S., Wang, X., Liu, S., & Ji, Y. (2018) · Annals of Human Genetics · doi:10.1111/ahg.12241 · Cited by 16 · cited 1×
“variants confer a 2- to 3-fold increased risk of FTD in European populations (101, 102).”
Background
Cited by
A predictive coding framework of allostatic–interoceptive overload in frontotemporal dementia
Migeot, J. A., Duran-Aniotz, C. A., Signorelli, C. M., Piguet, O., & Ibáñez, A. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.08.005 · Cited by 76
Self-citationA synergetic turn in cognitive neuroscience of brain diseases
Ibanez, A., Kringelbach, M. L., & Deco, G. (2024) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2023.12.006 · Cited by 65
Intrinsic timescales and predictive allostatic interoception in brain health and disease
Ibanez, A., & Northoff, G. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105510 · Cited by 36
Allostatic interoception and brain health: From neurodegeneration to social adversities
Migeot, J., & Ibáñez, A. (2025) · Encyclopedia of the Human Brain · doi:10.1016/b978-0-12-820480-1.00025-5 · Cited by 10
Self-citation
Metadata
- Authors
- Duran-Aniotz, C., Orellana, P., Leon Rodriguez, T., Henriquez, F., Cabello, V., Aguirre-Pinto, M. F., Escobedo, T., Takada, L. T., Pina-Escudero, S. D., Lopez, O., Yokoyama, J. S., Ibanez, A., Parra, M. A., & Slachevsky, A.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2021-06-24
- Volume
- 12
- Pages
- 663407-663407
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W3168390889
- Cited by
- 26
- References
- 66
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.